Kenneth Anderson, MD, from Harvard Medical School, Boston, MA, discusses the importance of measurable residual disease (MRD) as a prognostic marker and recent FDA approval of sequencing test for MRD in multiple myeloma (MM), with a number of clinical aspects to now consider. Dr Anderson also addresses the value of MRD as an endpoint in trials, with earlier surrogate markers now needed to discriminate between novel therapies. This interview took place at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018.

свернуть